Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Our leadership team inspires and challenges every aspect of the organization to develop life-changing solutions for the patients of today and tomorrow. Along with their peers who sit overseas, this dynamic and experienced group of U.S.-based leaders enable us to create innovative medicines that can change the standard of care.

Corporate Management Bio

Corporate Management

Ken Keller

Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business

Ken Takeshita, MD

Global Head, Research & Development

Daniel Switzer

Head of U.S. Oncology Business Division

Ken Keller

Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business

Rich Jones

Vice President, Global Oncology Business Strategy & Analytics

Ahmed Kotb, MD

Head of Global Oncology Medical Affairs

Ken Takeshita, MD

Global Head, Research & Development

Michael Grosso, MD, FACS

Global Head of Specialty Medicine Clinical Development

Dalal Nesheiwat, PharmD

Head of R&D Operations

Sandy Milligan, MD, JD

Head of Global Regulatory Affairs

Mark Rutstein, MD

Head of the Therapeutic Area Oncology

Michele Schmidt

Head of Asset Strategy & Project Management

Dale E. Shuster, PhD

Head of Global Precision Medicine

Daniel Switzer

Head of U.S. Oncology Business Division

Brian Hauser

Vice President, US Sales

Kara Reheis

Vice President, U.S. Marketing

Lerryn Trzcinski

Vice President, U.S. Market Access

Patricia L. Judson, M.D.

Head of U.S, Medical Affairs

Mark Chraplyvy

Vice President, US Business Operations

Stu Mackey, JD

Global Head Business Development

Matt Allegrucci

Chief Compliance Officer, Head of Global Compliance & Risk Management

James Felix

Head of Global Digital Transformation (DX), Chief Digital Transformation Officer

Amy Todd Klug, Esq.

General Counsel & Secretary

Simon King

Chief People Officer

Mila Tartakovsky

Head of US Finance and Global Oncology Finance

Last Updated: April 2025

Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Corporate Management Bio

Corporate Management

Ken Keller

Ken Takeshita, MD

Daniel Switzer

Global Oncology Business (U.S.-based leaders)

Ken Keller

Rich Jones

Ahmed Kotb, MD

Research & Development (U.S.-based leaders)

Ken Takeshita, MD

Michael Grosso, MD, FACS

Dalal Nesheiwat, PharmD

Sandy Milligan, MD, JD

Mark Rutstein, MD

Michele Schmidt

Dale E. Shuster, PhD

U.S. Oncology Business

Daniel Switzer

Brian Hauser

Kara Reheis

Lerryn Trzcinski

Patricia L. Judson, M.D.

Mark Chraplyvy

Other U.S.-based leaders

Stu Mackey, JD

Matt Allegrucci

James Felix

Amy Todd Klug, Esq.

Simon King

Mila Tartakovsky

Breadcrumb

Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Corporate Management Bio

Corporate Management

Ken Keller

Ken Takeshita, MD

Daniel Switzer

Global Oncology Business (U.S.-based leaders)

Ken Keller

Rich Jones

Ahmed Kotb, MD

Research & Development (U.S.-based leaders)

Ken Takeshita, MD

Michael Grosso, MD, FACS

Dalal Nesheiwat, PharmD

Sandy Milligan, MD, JD

Mark Rutstein, MD

Michele Schmidt

Dale E. Shuster, PhD

U.S. Oncology Business

Daniel Switzer

Brian Hauser

Kara Reheis

Lerryn Trzcinski

Patricia L. Judson, M.D.

Mark Chraplyvy

Other U.S.-based leaders

Stu Mackey, JD

Matt Allegrucci

James Felix

Amy Todd Klug, Esq.

Simon King

Mila Tartakovsky